S C Auld1, B K Moore2, R P Kyle3, B Eng4, K Nong4, E S Pevzner2, K K Eam5, M T Eang5, W P Killam4. 1. Division of Global HIV/TB, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA ; Division of Pulmonary and Critical Care Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. 2. Division of Global HIV/TB, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. 3. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada. 4. Division of Global HIV/TB, CDC, Phnom Penh, Cambodia. 5. National Center for Tuberculosis and Leprosy Control, Phnom Penh, Cambodia.
Abstract
SETTING: National Tuberculosis (TB) Program sites in northwest Cambodia. OBJECTIVE: To evaluate the impact of Xpert(®) MTB/RIF at point of care (POC) as compared to non-POC sites on the diagnostic evaluation of people living with the human immunodeficiency virus (PLHIV) with TB symptoms and patients with possible multidrug-resistant (MDR) TB. DESIGN: Observational cohort of patients undergoing routine diagnostic evaluation for TB following the rollout of Xpert. RESULTS: Between October 2011 and June 2013, 431 of 822 (52%) PLHIV with TB symptoms and 240/493 (49%) patients with possible MDR-TB underwent Xpert. Xpert was more likely to be performed when available as POC. A smaller proportion of PLHIV at POC sites were diagnosed with TB than at non-POC sites; however, at POC sites, a higher proportion of those diagnosed with TB were bacteriologically positive. There was poor agreement between Xpert and other tests such as smear microscopy and culture. Overall, the evaluation of patients with possible MDR-TB increased following Xpert rollout, yet for patients confirmed as having drug resistance on drug susceptibility testing, only 46% had rifampin resistance that would be identified with Xpert. CONCLUSION: Although utilization of Xpert was low, it may have contributed to an increase in evaluations for possible MDR-TB and a decline in empiric treatment for PLHIV when available as POC.
SETTING: National Tuberculosis (TB) Program sites in northwest Cambodia. OBJECTIVE: To evaluate the impact of Xpert(®) MTB/RIF at point of care (POC) as compared to non-POC sites on the diagnostic evaluation of people living with the human immunodeficiency virus (PLHIV) with TB symptoms and patients with possible multidrug-resistant (MDR) TB. DESIGN: Observational cohort of patients undergoing routine diagnostic evaluation for TB following the rollout of Xpert. RESULTS: Between October 2011 and June 2013, 431 of 822 (52%) PLHIV with TB symptoms and 240/493 (49%) patients with possible MDR-TB underwent Xpert. Xpert was more likely to be performed when available as POC. A smaller proportion of PLHIV at POC sites were diagnosed with TB than at non-POC sites; however, at POC sites, a higher proportion of those diagnosed with TB were bacteriologically positive. There was poor agreement between Xpert and other tests such as smear microscopy and culture. Overall, the evaluation of patients with possible MDR-TB increased following Xpert rollout, yet for patients confirmed as having drug resistance on drug susceptibility testing, only 46% had rifampin resistance that would be identified with Xpert. CONCLUSION: Although utilization of Xpert was low, it may have contributed to an increase in evaluations for possible MDR-TB and a decline in empiric treatment for PLHIV when available as POC.
Entities:
Keywords:
HIV; MDR-TB; drug resistance; point-of-care testing
Authors: Kimberly D McCarthy; Kevin P Cain; Kevin L Winthrop; Nibondh Udomsantisuk; Nguyen T N Lan; Borann Sar; Michael E Kimerling; Nong Kanara; Lut Lynen; Patama Monkongdee; Theerawit Tasaneeyapan; Jay K Varma Journal: Am J Respir Crit Care Med Date: 2012-02-16 Impact factor: 21.405
Authors: J Creswell; B Rai; R Wali; S Sudrungrot; L M Adhikari; R Pant; S Pyakurel; D Uranw; A J Codlin Journal: Int J Tuberc Lung Dis Date: 2015-05 Impact factor: 2.373
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: S C Auld; B K Moore; W P Killam; B Eng; K Nong; E C Pevzner; K K Eam; M T Eang; D Warren; S J Whitehead Journal: Public Health Action Date: 2014-12-21
Authors: L Mupfumi; B Makamure; M Chirehwa; T Sagonda; S Zinyowera; P Mason; J Z Metcalfe; R Mutetwa Journal: Open Forum Infect Dis Date: 2014-06-25 Impact factor: 3.835
Authors: Kuldeep Singh Sachdeva; Neeraj Raizada; Achuthan Sreenivas; Anna H Van't Hoog; Susan van den Hof; Puneet K Dewan; Rahul Thakur; R S Gupta; Shubhangi Kulsange; Bhavin Vadera; Ameet Babre; Christen Gray; Malik Parmar; Mayank Ghedia; Ranjani Ramachandran; Umesh Alavadi; Nimalan Arinaminpathy; Claudia Denkinger; Catharina Boehme; C N Paramasivan Journal: PLoS One Date: 2015-05-21 Impact factor: 3.240
Authors: Jacob Creswell; Andrew J Codlin; Emmanuel Andre; Mark A Micek; Ahmed Bedru; E Jane Carter; Rajendra-Prasad Yadav; Andrei Mosneaga; Bishwa Rai; Sayera Banu; Miranda Brouwer; Lucie Blok; Suvanand Sahu; Lucica Ditiu Journal: BMC Infect Dis Date: 2014-01-02 Impact factor: 3.090
Authors: Helen S Cox; Slindile Mbhele; Neisha Mohess; Andrew Whitelaw; Odelia Muller; Widaad Zemanay; Francesca Little; Virginia Azevedo; John Simpson; Catharina C Boehme; Mark P Nicol Journal: PLoS Med Date: 2014-11-25 Impact factor: 11.069
Authors: Lesley Scott; Pedro da Silva; Catharina C Boehme; Wendy Stevens; Christopher M Gilpin Journal: Curr Opin HIV AIDS Date: 2017-03 Impact factor: 4.283
Authors: David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart Journal: Cochrane Database Syst Rev Date: 2019-06-07
Authors: Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne Journal: Cochrane Database Syst Rev Date: 2021-03-23